75 related articles for article (PubMed ID: 7720109)
21. [Flow cytometry-pathology combined study of breast cancer].
Yu ZY; Yu JM; Wu TH; Zhuo PY; Wang SF; Li M; Zhang X; Lü BY; Liu YB
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):420-2. PubMed ID: 16188128
[TBL] [Abstract][Full Text] [Related]
22. [P21 expression of ras oncogene product in benign and malignant female mammary lesions].
Zhang JZ; Fan SC; Liu HF
Zhonghua Bing Li Xue Za Zhi; 1994 Oct; 23(5):302-3. PubMed ID: 7874767
[TBL] [Abstract][Full Text] [Related]
23. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
24. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
25. p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer.
Brotherick I; Shenton BK; Cowan WK; Angus B; Horne CH; Higgs MJ; Lennard TW
Cancer Immunol Immunother; 1995 Sep; 41(3):146-50. PubMed ID: 7553682
[TBL] [Abstract][Full Text] [Related]
26. p53 protein expression and nuclear DNA content in breast intraductal proliferations.
Schmitt FC; Leal C; Lopes C
J Pathol; 1995 Jul; 176(3):233-41. PubMed ID: 7674086
[TBL] [Abstract][Full Text] [Related]
27. [An immunohistochemical study of the relationship between p53 expression and the DNA ploidy pattern using image cytometry in colorectal carcinoma].
Miki T; Funahashi K; Tsujita K; Takatsuki M; Koike J; Kubota S; Goto T; Nagasawa Y; Kobayashi K; Yanagita K
Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():130-3. PubMed ID: 7611775
[TBL] [Abstract][Full Text] [Related]
28. The correlation between the expression of p53 protein and DNA ploidy in patients with gastric cancer that has invaded the serosa.
Wang Z; Ikeguchi M; Maeta M; Kaibara N
Anticancer Res; 1997; 17(5A):3701-5. PubMed ID: 9413227
[TBL] [Abstract][Full Text] [Related]
29. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study.
Rohan TE; Li SQ; Hartwick R; Kandel RA
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1316-23. PubMed ID: 16835330
[TBL] [Abstract][Full Text] [Related]
30. Expression of centrosomal tubulins associated with DNA ploidy in breast premalignant lesions and carcinoma.
Niu Y; Wang S; Liu T; Zhang T; Wei X; Wang Y; Jiang L
Pathol Res Pract; 2013 Apr; 209(4):221-7. PubMed ID: 23523041
[TBL] [Abstract][Full Text] [Related]
31. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer.
Yildirim-Assaf S; Coumbos A; Hopfenmüller W; Foss HD; Stein H; Kühn W
J Clin Pathol; 2007 Jun; 60(6):649-55. PubMed ID: 17557867
[TBL] [Abstract][Full Text] [Related]
33. p53 tumor suppressor protein and tissue proliferative fraction in infiltrating duct carcinoma.
Kesari AL; Chellam VG; Nair PP; Ahmed I; Madhavan J; Thomas PA; Nair MK; Pillai MR
J Surg Oncol; 1997 Jul; 65(3):159-63. PubMed ID: 9236923
[TBL] [Abstract][Full Text] [Related]
34. Proliferating cell nuclear antigen (PCNA) expression in patients with breast carcinoma in comparison to patients with benign breast diseases.
Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G
In Vivo; 1994; 8(6):1053-6. PubMed ID: 7772736
[TBL] [Abstract][Full Text] [Related]
35. [The relationships among DNA ploidy type determined by laser scanning cytometry, the overexpression of p53 protein and the numerical aberrations of chromosome 7 in bladder cancer].
Kawamura K; Ikeda R; Suzuki K
Hinyokika Kiyo; 2000 Jun; 46(6):377-83. PubMed ID: 10934605
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
38. p53 expression in cytologic specimens from benign and malignant breast lesions.
Koutselini H; Malliri A; Field JK; Spandidos DA
Anticancer Res; 1991; 11(4):1415-9. PubMed ID: 1746898
[TBL] [Abstract][Full Text] [Related]
39. Mouse mammary tumor-like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer.
Faedo M; Ford CE; Mehta R; Blazek K; Rawlinson WD
Clin Cancer Res; 2004 Jul; 10(13):4417-9. PubMed ID: 15240531
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical study of apoptotic marker p53 as a prognostic factor in breast cancer.
Loskutova KS; Kirillina MP; Lushnikova EL; Nepomnyashchikh LM
Bull Exp Biol Med; 2014 Nov; 158(1):84-7. PubMed ID: 25403404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
